Prediction of survival and cancer recurrence using F-18 FDG PET/CT in patients with surgically resected early stage (stage I and II) non-small cell lung cancer

Neoplasma

Volumn 58, Issue 3, 2011, Pages 245-250

  Kim, Y S ^a   Kim, S J ^a   Kim, Y K ^b   Kim, I J ^a   Kim, Y D ^a   Lee, M K ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Private Clinic of Internal Medicine   (South Korea)

Author keywords

Disease free survival; Early stage; F 18 FDG; Non small cell lung cancer; Overall survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; EARLY CANCER; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79961121833     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_245     Document Type: Article

References (23)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, XU J, ET et al. Cancer Statistics, 2008. CA Cancer J Clin 2008;58:71-96. doi:10.3322/CA.2007.0010
2. Martini N, BAINS MS, BURT ME, ZAKOWSKI MF, MC-CORMACK P, et al. Incidence and local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995;109:120-129. misctextdoi:10.1016/S0022-5223(95)70427-2/misctext
3. GOYA T, ASAMURA H, YOSHIMURA H, KATO H, SHIMOKATA K, et al. Prognosis of 6644 resected nonsmall cell lung cancers in Japan: A Japanese lung cancer registry study. Lung Cancer 2005;50:227-234. doi:10.1016/ j.lungcan.2005.05.021
4. HARPOLE DH JR, HERNDON JE 2ND, YOUNG WG JR, WOLFE WG, SABISTON DC JR. Stage I non-small cell lung cancer: A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995;76:787-796. doi:10.1002/1097-0142(19950901)76:5<787:: AID-CNCR2820760512>3.0.CO;2-Q
5. WILLIAMS DE, PAIROLERO PC, DAVIS CS, BERNATZ PE, PAYNE WS, et al. Survival of patients surgically treated for stage I lung cancer. J Thorac Cardiovasc Surg 1981;82:70-76.
6. WISNIVESKY JP, HENSCHKE C, MCGINN T, IANNUZZI MC. Prognosis of Stage II non-small cell lung cancer according to tumor and nodal status at diagnosis. Lung Cancer 2005; 49:181-186. doi:10.1016/j.lungcan.2005.02.010
7. MOUNTAIN CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. doi:10.1378/chest.111.6.1710
8. MOLDVAY J, SCHEID P, WILD P, NABIL K, SIAT J, et al. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 2000;6:1125-1134.
9. BILLE A, PELOSI E, SKANJETI A, ARENA V, ERRICO L, et al. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg. 2009;36:440-445. doi:10.1016/ j.ejcts.2009.04.003
10. HICKS RJ. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50 Suppl 1:31S-42S. doi:10.2967/jnumed.108.057216
11. AL-SARRAF N, GATELY K, LUCEY J, AZIZ R, DODDAKU-LA K, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: analysis of 176 cases. Eur J Cardiothorac Surg. 2008;34:892-897. doi:10.1016/ j.ejcts.2008.07.023
12. UNG YC, MAZIAK DE, VANDERVEEN JA, SMITH CA, GULENCHYN K, et al. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care: 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst. 2007;99:1753-1767.
13. DE GEU-SOEI LF, VAN DER HEIJDEN HF, CORSTENS FH, OYEN WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. J Nucl Med. 2007;48:1592-1598.
14. SCHREVENS L, LORENT N, DOOMS C, VANSTEENKISTE J. The role of PET scan in diagnosis, staging, and management of non-small cell lung cancer. Oncologist. 2004;9:633-643. misctextdoi:10.1634/theoncologist.9-6-633/misctext
15. UKENA D, HELLWIG D. Value of FDG PET in the man-agement of NSCLC. Lung Cancer. 2004;45 Suppl 2:S75-78. doi:10.1016/j.lungcan.2004.07.989
16. HANIN FX, LONNEUX M, CORNET J, NOIRHOMME P, COULON C, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg. 2008;33:819-823. doi:10.1016/j.ejcts.2008.02.005
17. GOODGAME B, PILLOT GA, YANG Z, SHRIKI J, MEY-ERS BF, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol. 2008;3:130-134. misctextdoi:10.1097//misctextJTO.0b013e318160c122
18. UM SW, KIM H, KOH WJ, SUH GY, CHUNG MP, et al. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2009;4:1331-1336. misctextdoi:10.1097//misctextJTO.0b013e3181b6be3e
19. KIM HR, KIM DJ, LEE WW, JHEON S, SUNG SW. The significance of maximum standardized uptake values in patients with stage I pulmonary adenocarcinoma. Eur J Cardiothorac Surg. 2009;35:712-716. doi:10.1016/j.ejcts.2008.12.030
20. DOOMS C, VAN BAARDWIJK A, VERBEKEN E, VAN SUYLEN RJ, STROOBANTS S, et al. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer. J Thorac Oncol. 2009;4:822-828. doi:10.1097/JTO.0b013e3181a97df7
21. NAIR VS, KRUPITSKAYA Y, GOULD MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol. 2009;4:1473-1479. misctextdoi:10.1097/JTO.0b013e3181bccbc6/misctext
22. OHTSUKA T, NOMORI H, WATANABE K, KAJI M, NARUKE T, et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer. 2006;107:2468-2473. doi:10.1002/cncr.22268
23. AGARWAL M, BRAHMANDAY G, BAJAJ SK, RA-VIKRISHNAN KP, WONG CY. Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC). Eur J Nucl Med Mol Imaging. 2010;37:691-698. doi:10.1007/s00259-009-1291-x